In the development of new vaccine the fate of preparation depends on three main factors: potential to decrease morbidity and benefits from vaccine use; the risk of post vaccinal complications and possible damage from vaccination; the cost of vaccine and economic advantages. By basic parameters, dealing with safety and effectiveness, home immunological preparations, first of all vaccines used in framework of vaccination calendar, meet all the requirements of WHO. However, absolutely safe vaccines don't exist in the world. All the above may be an evidence of the need to find new approaches to the development of more improved vaccines. Gene-engineering technology is a revolutionary event in vaccinology, it made it possible to develop recombinant vaccines, possessing weak reactogenity and sufficient effectivity. Anti-idiotypic vaccines didn't go out the sphere of experimental approaches. Any protein vaccine, being introduced to the body, is undergone to digestion. Forming peptides interact with histocompatibility antigens and acquire immunogenic properties. The development of new class vaccines is based on this principle. Synthetic peptide vaccines are safe and low reactogenic. In spite of a large amount of experimental peptide vaccines, there is no still any vaccine of such a type in the practice of health services. Meanwhile, WHO gave recommendations dealing with development and control of peptide vaccines, suggesting that such vaccines will appear in the next future. The same recommendations were given for so called DNA vaccines.
Download full-text PDF |
Source |
---|
Genomics Proteomics Bioinformatics
January 2025
Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA.
Tumor-specific antigens, also known as neoantigens, have potential utility in anti-cancer immunotherapy, including immune checkpoint blockade (ICB), neoantigen-specific T cell receptor-engineered T (TCR-T), chimeric antigen receptor T (CAR-T), and therapeutic cancer vaccines (TCVs). After recognizing presented neoantigens, the immune system becomes activated and triggers the death of tumor cells. Neoantigens may be derived from multiple origins, including somatic mutations (single nucleotide variants, insertion/deletions, and gene fusions), circular RNAs, alternative splicing, RNA editing, and polymorphic microbiome.
View Article and Find Full Text PDFLeuk Res
January 2025
Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima, Japan. Electronic address:
The standard treatment for aggressive adult T-cell leukemia/lymphoma (ATL) is multi-agent chemotherapy, but the use of more intense cytotoxic anticancer agents is becoming more difficult with the aging of patients at the time of diagnosis. As a means of overcoming this hurdle, antibody drugs, which are supposed to be less toxic, have been developed for ATL. The advent of the anti-CC chemokine receptor 4 (CCR4) antibody mogamulizumab has significantly advanced ATL treatment.
View Article and Find Full Text PDFNPJ Vaccines
January 2025
Department of Gastroenterology & Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Synthetic long peptides (SLPs) are a promising vaccine modality that exploit dendritic cells (DC) to treat chronic infections or cancer. Currently, the design of SLPs relies on in silico prediction and multifactorial T cells assays to determine which SLPs are best cross-presented on DC human leukocyte antigen class I (HLA-I). Furthermore, it is unknown how TLR ligand-based adjuvants affect DC cross-presentation.
View Article and Find Full Text PDFInt J Pharm
January 2025
State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.. Electronic address:
Background: African swine fever (ASF) is a highly contagious disease, and the core-shell protein p34 is an important antigen that can induce immune responses. The use of ferritin nanoparticles for the orderly and repetitive display of antigens on the particle surface can improve the immunogenicity of subunit vaccines. Here, we used the SpyCatcher/Spytag system to conjugate ferritin nanoparticles with the p34 protein (F-p34).
View Article and Find Full Text PDFHuman epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!